OptimizeRx Corporation: nonoperating income or expense
Nonoperating income or expense for OptimizeRx Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All OptimizeRx Corporation financial histories
What this measure means
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
Exact concept: us-gaap:NonoperatingIncomeExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -4,743,000 | USD | 2026-03-12 | 10-K · 0001448431-26-000005 |
| 2024-01-01 | 2024-12-31 | -5,679,000 | USD | 2026-03-12 | 10-K · 0001448431-26-000005 |
| 2023-01-01 | 2023-12-31 | 1,238,000 | USD | 2025-03-20 | 10-K · 0001213900-25-025576 |
| 2022-01-01 | 2022-12-31 | 852,298 | USD | 2024-04-15 | 10-K · 0001213900-24-033000 |
| 2018-01-01 | 2018-12-31 | 46,212 | USD | 2019-03-12 | 10-K · 0001213900-19-003962 |
| 2017-01-01 | 2017-12-31 | 25,937 | USD | 2019-03-12 | 10-K · 0001213900-19-003962 |
| 2016-01-01 | 2016-12-31 | 42,309 | USD | 2018-03-08 | 10-K · 0001213900-18-002722 |
| 2015-01-01 | 2015-12-31 | 2,267 | USD | 2017-03-08 | 10-K · 0001213900-17-002093 |
| 2014-01-01 | 2014-12-31 | 935 | USD | 2016-03-15 | 10-K · 0001213900-16-011609 |
| 2013-01-01 | 2013-12-31 | 246 | USD | 2015-09-16 | 10-K · 0001213900-15-007027 |
Related financial histories
- OptimizeRx Corporation: total assets
- OptimizeRx Corporation: total liabilities
- OptimizeRx Corporation: stockholders equity
- OptimizeRx Corporation: cash and cash equivalents
- OptimizeRx Corporation: net income or loss
- OptimizeRx Corporation: operating cash flow
- OptimizeRx Corporation: capital expenditure payments
- OptimizeRx Corporation: revenue
- OptimizeRx Corporation: contract revenue excluding tax
- OptimizeRx Corporation: financing cash flow
- OptimizeRx Corporation: investing cash flow
- OptimizeRx Corporation: retained earnings or deficit
- OptimizeRx Corporation: basic weighted-average shares
- OptimizeRx Corporation: diluted weighted-average shares
- OptimizeRx Corporation: basic earnings per share
- OptimizeRx Corporation: diluted earnings per share
- OptimizeRx Corporation: income tax expense or benefit
- OptimizeRx Corporation: net property, plant and equipment
- OptimizeRx Corporation: share-based compensation expense
- OptimizeRx Corporation: operating income or loss
- OptimizeRx Corporation: current assets
- OptimizeRx Corporation: interest expense
- OptimizeRx Corporation: current liabilities
- OptimizeRx Corporation: goodwill carrying amount
- OptimizeRx Corporation: net finite-lived intangible assets
- OptimizeRx Corporation: net current accounts receivable
- OptimizeRx Corporation: common-stock repurchase payments
- OptimizeRx Corporation: operating expenses
- OptimizeRx Corporation: gross profit
- OptimizeRx Corporation: cost of revenue
- OptimizeRx Corporation: research and development expense
- OptimizeRx Corporation: common shares outstanding
- OptimizeRx Corporation: cash including restricted cash
- OptimizeRx Corporation: additional paid-in capital
- OptimizeRx Corporation: operating lease right-of-use asset
- OptimizeRx Corporation: operating lease liability
- OptimizeRx Corporation: long-term debt
- OptimizeRx Corporation: gross property, plant and equipment
- OptimizeRx Corporation: accumulated depreciation on property, plant and equipment
- OptimizeRx Corporation: net intangible assets excluding goodwill
- OptimizeRx Corporation: accrued current liabilities
- OptimizeRx Corporation: prepaid expenses and other current assets
- OptimizeRx Corporation: current contract liabilities
- OptimizeRx Corporation: net deferred tax assets
- OptimizeRx Corporation: net deferred tax liabilities
- OptimizeRx Corporation: pre-tax income or loss from continuing operations
- OptimizeRx Corporation: profit or loss including noncontrolling interests
- OptimizeRx Corporation: net income available to common stockholders
- OptimizeRx Corporation: general and administrative expense
- OptimizeRx Corporation: depreciation expense
- OptimizeRx Corporation: depreciation, depletion and amortization
- OptimizeRx Corporation: amortization of intangible assets
- OptimizeRx Corporation: nonoperating interest expense
- OptimizeRx Corporation: other nonoperating income or expense
- OptimizeRx Corporation: current income tax expense or benefit
- OptimizeRx Corporation: deferred income tax expense or benefit
- OptimizeRx Corporation: interest paid, net
- OptimizeRx Corporation: income taxes paid, net
- OptimizeRx Corporation: proceeds from issuing common stock
- OptimizeRx Corporation: change in accounts receivable
- OptimizeRx Corporation: change in accounts payable
Inspect the source
- Entity
- OptimizeRx Corporation / CIK 0001448431
- Captured
- 2026-09-20T09:05:08.152Z
- SEC response SHA-256
e280d2de9ab6667276acbbb5def7abe84fc4602cbf3198471c8ba2bbfd13a64f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001448431.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))